Opinion

Video

AUA 2024: Outlining BOND-003 Data for NMIBC Therapy

Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Video content above is prompted by the following question(s):

  • Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.